Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cilostazol + probucol
- Development stage
- Preclinical
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cilostazol + probucol is a combination therapy of two small molecule drugs, cilostazol and probucol. Cilostazol is an antiplatelet agent and vasodilator that acts as a phosphodiesterase 3 (PDE3) inhibitor, increasing cAMP levels in platelets and blood vessels to inhibit platelet aggregation and promote vasodilation[1][4]. Probucol is a lipid-lowering agent with antioxidant properties that activates cholesteryl ester transfer protein, reduces LDL cholesterol, inhibits inflammation, and stabilizes atherosclerotic plaques[5][6]. The combination has been studied for its potential synergistic effects in preventing restenosis after percutaneous coronary interventions, improving endothelial function in patients with hypercholesterolemia or subclinical lacunar infarction (SLCI), reducing inflammation associated with atherosclerosis, and possibly attenuating cognitive decline after stroke by targeting vascular risk factors[3][4][5][6].
- Other names
- cilostazol, probucolprobucol and cilostazolprobucol plus cilostazol
02
Targets
CETPPDE3B (Phosphodiesterase 3B)PDE3A (Phosphodiesterase 3A)
Beyond the preview
Go deeper on cilostazol + probucol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cilostazol + probucol.